-
2024-517419-62-00
4
2025-02-28
HER2 mutation
-
2023-510292-65-00
5
2025-02-25
chronic graft-versus-host disease
-
2023-507227-36-00
5
2025-02-21
SARS-CoV-2 (COVID-19) infection
-
2024-511652-40-00
5
2025-02-05
METASTATIC CASTRATION RESISTANT PROSTATE CANCER
-
2023-508234-34-00
4
2025-01-27
Crohn's disease
-
2023-509963-25-00
4
2025-01-17
Fluoropyrimidine (FP)-naive patients with gastrointestinal (GI) cancer
-
2023-510109-16-00
4
2025-01-06
Acute Respiratory Distress Syndrome (ARDS) Due to Pneumonia or other I
-
2024-511188-26-00
5
2024-12-20
Relapsed/refractory multiple myeloma in patients who have received 1 t
-
2023-508724-35-00
4
2024-12-10
Patients with pMMR/MSS metastatic adenocarcinoma of the colon or rectu
-
2023-510380-34-00
4
2024-12-10
Diffuse cutaneous systemic sclerosis (dcSSc)
-
2024-516109-21-00
5
2024-12-09
Polycythaemia Vera (PV)
-
2024-510718-34-00
11
2024-11-29
Membranous nephropathy
-
2024-513009-30-00
4
2024-11-21
Moderate to Severe Crohn’s Disease
-
2024-513098-31-00
4
2024-11-14
Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma
-
2024-518813-24-00
1
2024-11-12
Patients with Relapsed/Refractory Acute Myeloid Leukemia or High/Very-
-
2024-514886-21-00
6
2024-11-06
Pemphigus diseases (Pemphigus Vulgaris - PV and Pemphigus Foliaceus
(P
-
2024-516242-19-00
5
2024-11-05
lupus nephritis
-
2023-509340-10-00
5
2024-10-29
Patients with HLA-A2 positive phenotype and metastatic Non-Small Cell
-
2024-511319-91-00
5
2024-10-23
Advanced non-small cell lung cancer with HER2 (ERBB2) mutation
-
2024-514241-10-00
4
2024-10-22
Kaposi's sarcoma
-
2023-504724-25-00
5
2024-10-16
Primary Myelofibrosis
-
2024-511070-68-01
5
2024-09-24
Ampullary adenocarcinoma
-
2024-513087-26-00
5
2024-09-10
Metastatic Non-small Cell Lung Cancer
-
2024-515118-42-00
11
2024-09-10
Colorectal cancer